{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:19:08Z","timestamp":1789611548319,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["5U19AI166798-02"],"award-info":[{"award-number":["5U19AI166798-02"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UC-Davis Burden Family Gift Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Isavuconazole is efficacious in the treatment of aspergillosis, mucormycosis, and other invasive fungal infections. Therapeutic drug monitoring is generally not assessed during treatment with isavuconazole due to its high oral bioavailability, modest drug\u2013drug interactions, and linear pharmacokinetics. This study aimed to determine whether an exposure\u2013toxicity relationship exists for isavuconazole in those experiencing potential adverse drug events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analysed adult outpatients receiving isavuconazole and the occurrence of adverse events. Patients with and without adverse events were compared to identify serum drug concentrations predictive of potential drug-related toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-five patients, corresponding to 219 serum levels total, were analysed. Thirty-seven (38.9%) developed adverse events, most commonly transaminitis (29.7%), diarrhoea (24.3%), and nausea (18.9%). Using Youden\u2019s index, a serum level of 5.86\u2005\u00b5g\/mL corresponded to a threshold balancing sensitivity (41.0%) and specificity (87.1%) in the determination of toxicity risk. All 24 patients undergoing isavuconazole dose reduction demonstrated resolution of symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identified an exposure\u2013toxicity relationship for isavuconazole. Therapeutic drug monitoring may be beneficial for those on isavuconazole therapy who develop signs or symptoms of potential toxicity. Additionally, in patients with adverse events attributed to isavuconazole, dose reduction often led to resolution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf128","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:45:24Z","timestamp":1744271124000},"page":"1702-1706","source":"Crossref","is-referenced-by-count":20,"title":["Isavuconazole therapeutic drug monitoring and association with adverse events"],"prefix":"10.1093","volume":"80","author":[{"given":"Emily","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of California-Davis Health , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wittenberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California-Davis Health , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Vongspanich","family":"Dray","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California-Davis Health , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-9383","authenticated-orcid":false,"given":"Jeffrey","family":"Fine","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Division of Biostatistics, Clinical and Translational Science Center, University of California-Davis , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Robison","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of California-Davis Health , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1734-2755","authenticated-orcid":false,"given":"Machelle","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Division of Biostatistics, Clinical and Translational Science Center, University of California-Davis , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Trigg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of California-Davis Health , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J","family":"Bays","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of California-Davis Health , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Chee","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Division of Biostatistics, Clinical and Translational Science Center, University of California-Davis , Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of California-Davis Health , Sacramento, CA, USA"},{"name":"Department of Medical Microbiology and Immunology, University of California-Davis , Davis, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2025060219530010500_dkaf128-B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530010500_dkaf128-B2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025060219530010500_dkaf128-B3","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025060219530010500_dkaf128-B4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025060219530010500_dkaf128-B5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2025060219530010500_dkaf128-B6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025060219530010500_dkaf128-B7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025060219530010500_dkaf128-B8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025060219530010500_dkaf128-B9","doi-asserted-by":"publisher","first-page":"e02232-18","DOI":"10.1128\/AAC.02232-18","article-title":"Isavuconazole in the treatment of coccidioidal meningitis","volume":"63","author":"Heidari","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530010500_dkaf128-B10","doi-asserted-by":"publisher","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530010500_dkaf128-B11"},{"key":"2025060219530010500_dkaf128-B12","doi-asserted-by":"publisher","first-page":"e01384-18","DOI":"10.1128\/AAC.01384-18","article-title":"Examination of fluconazole-induced alopecia in an animal model and human cohort","volume":"63","author":"Thompson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530010500_dkaf128-B13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025060219530010500_dkaf128-B14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025060219530010500_dkaf128-B15","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025060219530010500_dkaf128-B16","doi-asserted-by":"publisher","first-page":"e01511-20","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1702\/63016852\/dkaf128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1702\/63016852\/dkaf128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:53:14Z","timestamp":1748893994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/6\/1702\/8120692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,28]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf128","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,28]]}}}